Market Access The benefits of ePI for patients and the planet With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.
Market Access Exploring the potential of FHIRs and e-labelling Fast Healthcare Interoperability Resources (FHIRs) allow fast to bu
News Data at EULAR back Biogen, UCB's first-in-class lupus drug Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face